{
    "clinical_study": {
        "@rank": "128017", 
        "brief_summary": {
            "textblock": "RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells.\n      CT-guided radiofrequency ablation may be effective treatment for lung cancer.\n\n      PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating\n      patients who have refractory or advanced lung cancer."
        }, 
        "brief_title": "Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer", 
        "condition": [
            "Lung Cancer", 
            "Malignant Mesothelioma", 
            "Metastatic Cancer", 
            "Thymoma and Thymic Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Lung Neoplasms", 
                "Mesothelioma", 
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary", 
                "Thymoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the safety and toxicity of radiofrequency ablation in patients with\n           refractory or advanced pulmonary malignancies.\n\n        -  Determine the efficacy of this treatment, in terms of local control, in these patients.\n\n        -  Determine whether CT scan is a reasonable imaging assessment tool for treatment\n           delivery and follow-up in these patients.\n\n      OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the\n      tumor over 2 hours.\n\n      Patients are followed at 1, 3, 6, and 12 months.\n\n      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of a primary or secondary intrathoracic malignancy\n\n               -  Any cell type or origin\n\n               -  Involving the intrapulmonary, mediastinal, or pleural/chest wall\n\n               -  Inoperable primary or metastatic cancer to the lung\n\n          -  Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy,\n             or radiotherapy)\n\n          -  Single or multiple lesions that are non-contiguous with vital structures or organs\n             such as:\n\n          -  Trachea\n\n          -  Heart\n\n          -  Aorta\n\n          -  Great vessels\n\n          -  Esophagus\n\n          -  Less than 5 cm in largest dimension\n\n          -  Accessible via percutaneous transthoracic route\n\n          -  Hepatic:\n\n               -  Coagulation profile normal"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00024076", 
            "org_study_id": "CDR0000068889", 
            "secondary_id": [
                "P30CA016042", 
                "UCLA-9908024", 
                "NCI-G01-2011"
            ]
        }, 
        "intervention": {
            "intervention_name": "radiofrequency ablation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "recurrent non-small cell lung cancer", 
            "recurrent small cell lung cancer", 
            "recurrent malignant mesothelioma", 
            "recurrent thymoma and thymic carcinoma", 
            "stage IIIB non-small cell lung cancer", 
            "stage IV non-small cell lung cancer", 
            "pulmonary carcinoid tumor", 
            "lung metastases"
        ], 
        "lastchanged_date": "July 27, 2012", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/UCLA-9908024"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095-1781"
                }, 
                "name": "Jonsson Comprehensive Cancer Center, UCLA"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Radiofrequency Ablation of Pulmonary Malignancy", 
        "overall_official": {
            "affiliation": "Jonsson Comprehensive Cancer Center", 
            "last_name": "Robert D. Suh, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2006", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00024076"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jonsson Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Jonsson Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2000", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "Jonsson Comprehensive Cancer Center, UCLA": "34.052 -118.244"
    }
}